36
Participants
Start Date
April 21, 2017
Primary Completion Date
April 7, 2022
Study Completion Date
April 7, 2022
Methylphenidate, aripiprazole, and combination
Methylphenidate (4 weeks), aripiprazole (4 weeks), and the combination (2weeks). The primary outcome was improvement of irritability as measured by Aberrant Behavior Checklist-irritability subscale (ABC-I). During the first step, the subjects received pharmacological treatment of methylphenidate with flexible dosage for 4 weeks. Those subjects who had suboptimal response to methylphenidate (reduction of ABC-I score \< 25%) entered the second step and the medication was switched to aripiprazole. After 4 weeks of treatment, those whose ABC-I scores reduced \< 25% entered the third step and received the treatment of combination of methylphenidate and aripiprazole for two weeks (3rd step).
Tri-Service General Hospital, National Defense Medical Center, Taipei
Tri-Service General Hospital
OTHER